Internal Medicine Medical Specialties Press Urology

Study Reveals Possible Drug Treatment for Lupus Kidney Disease

The National Kidney Foundation (NKF) showcased a global study designed to understand the experimental immunosuppressant drug Voclosporin as a treatment for patients with lupus kidney disease.

The important study, “AURORA Phase 3 Trial Demonstrates Voclosporin Statistical Superiority Over Standard of Care in Lupus Nephritis (LN),” was selected as a late-breaking poster presentation chosen from among hundreds of other discoveries presented at the foundation’s annual Spring Clinical Meetings.

Aurora is a global study designed to help us understand if adding voclosporin to mycophenolate mofetil (MMF) and steroids, common treatments for lupus kidney disease, will improve outcomes in patients with active lupus kidney disease. Voclosporin is being developed by Aurinia Pharmaceuticals.

“We are pleased to report that the patients who received voclosporin were 2.65 times more likely to meet the criteria for response based on proteinuria and eGFR,” said lead investigator Keisha L. Gibson, MD MPH FASN, Associate Professor of Medicine and Pediatrics, DOM Vice Chair of Diversity and Inclusion Chief, Pediatric Nephrology, UNC Kidney Center. “There were no differences in the safety profile between the voclosporin and standard care groups.

“We know that achieving remission status in lupus kidney disease correlates with good long-term kidney survival and so the results of this study are very encouraging,” added Dr. Gibson.

Based on the results of this study, Aurinia plans to file an application with the FDA for approval, which if approved, will open access to this medication to patients with lupus kidney disease. In the meantime, many participants that have completed the study will roll over into a 2-year extension, Dr. Gibson said.

This year’s Spring Clinical Meetings are a Live-Virtual Meeting due to the COVID-19 outbreak. This necessary change will help ensure the safety of our patients, staff, volunteers and conference participants while still enabling NKF to provide the high-quality content SCM is known for in a new live-virtual format. 

Meeta Ramnani
Meeta Ramnani
Meeta develops credible content about various markets based on deep research, opinions from experts and inputs from industry leaders. As the managing editor at Smart Industry News, she assures that every piece of news and article adds to the knowledge of decision makers. An avid bike rider, Meeta, is a postgraduate from Indian Institute of Journalism and New Media (IIJNM) Bangalore, where her specialization was Business Journalism. She carries experience from mainstream print media including The Times Group and Sakal Media Group.
https://smarthealthcarenews.com/